GtoPdb Ligand ID: 8719

Synonyms: ch38SB19 | hu38SB19 | isatuximab-irfc | SAR-650984 | SAR650984 | Sarclisa®
isatuximab is an approved drug (FDA (2020))
Compound class: Antibody
Comment: Isatuximab is an anti-CD38 monoclonal antibody that was designed for anti-tumour potential [2].
A patent search identifies the peptide sequences of the light and heavy chain variable regions of isatuximab as SEQ ID NO: 22 and SEQ ID NO: 21 from patent US 8877899 B2 [6] (and equates to Ref mAB5 in the patent document). This patent further refers these sequences to WO2008047242 A8, but neither this or any associated patent (eg US20110262454 A1) provide peptide sequences to allow identification of isatuximab therein. The most likely patent defined embodiment being isatuximab is hu38SB19 [4].
Bioactivity Comments
The affinity values in the table below represents the Kds provided in US20110262454 A1 [4] for a range of tested CD38-binding antibodies. The Kd for hu38SB19 is 0.23 nM [4].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD38 Hs Antibody Binding 8.5 – 10.0 pKd - 4
pKd 8.5 – 10.0 (Kd 3x10-9 – 1x10-10 M) [4]